Physician profile
Michael Josovitz
NPI 1538152459
$2,566.66
in general payments reported to CMS, 2019-2025
13 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $241 · 2021: $375 · 2022: $125 · 2023: $138 · 2024: $260 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032 · Education: $23.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.24 |
| Education | $23.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.00 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $380.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $329.52 | 2019-2025 | Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $249.97 | 2019-2025 | Camzyos |
| Novo Nordisk INC | $151.60 | 2019-2025 | Ozempic |
| Phathom Pharmaceuticals, INC. | $146.26 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $126.07 | 2025 | Nuzyra, Xhance |
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Abbvie INC. | $125.00 | 2022 | |
| Boston Scientific Corporation | $98.98 | 2020 | |
| Astellas Pharma US INC | $30.38 | 2025 | Veozah |
| Verona Pharma, INC. | $30.00 | 2025 | Ohtuvayre |
| Opko Pharmaceuticals, LLC | $23.81 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Josovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.